TY - JOUR T1 - A pilot study on changes of macrophage colony stimulating factor and transforming growth factor β1 in male patients with ankylosing spondylitis taking thalidomide JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 781 LP - 782 DO - 10.1136/ard.2009.114397 VL - 69 IS - 4 AU - PT Yang AU - WG Xiao AU - L Qin AU - LJ Zhao AU - LM He AU - M Ito Y1 - 2010/04/01 UR - http://ard.bmj.com/content/69/4/781.abstract N2 - Ankylosing spondylitis (AS) is a progressive disease of which spinal fusion is the clinical and pathological hallmark. Thalidomide has some efficacy in treating axial inflammation in AS.1 Here, we report clinical responses and changes of serum macrophage colony stimulating factor (M-CSF) and transforming growth factor β1 (TGFβ1) in Chinese male patients with active AS taking thalidomide.This study enrolled 29 male patients with active AS, whose Bath ankylosing spondylitis disease activity index (BASDAI) was 3 or above.2 A total of 16 patients not intending to have children within the next 2 years took thalidomide (75 mg every night postoperatively) and diclofenac sodium (50 mg 3 times a day postoperatively) for 12 weeks; other patients took diclofenac sodium (50 mg 3 times a day postoperatively) alone. There were no … ER -